wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q30249003-2055459E-EF38-4909-B443-1E9E3089A045
Q30249003-2055459E-EF38-4909-B443-1E9E3089A045
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30249003-2055459E-EF38-4909-B443-1E9E3089A045
Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature.
P2860
Q30249003-2055459E-EF38-4909-B443-1E9E3089A045
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30249003-2055459E-EF38-4909-B443-1E9E3089A045
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b7f9225e8abf963f0ce27f46a59b13377db9780a
P2860
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.